Retrospective nationwide study on the trends in first-line antidiabetic medication for patients with type 2 diabetes in Japan.

Ryotaro BouchiTakehiro SugiyamaAtsushi GotoKenjiro ImaiNoriko Ihana-SugiyamaMitsuru OhsugiToshimasa YamauchiTakashi KadowakiKohjiro Ueki

Published in: Journal of diabetes investigation (2021)

Unlike in the USA and Europe, dipeptidyl peptidase-4 inhibitor is the most prescribed first-line medication for type 2 diabetes patients in Japan, while there is a wide variation in the drug choice by facility-type and prefecture.

Keyphrases

type diabetes
end stage renal disease
newly diagnosed
adverse drug
healthcare
ejection fraction
prognostic factors
peritoneal dialysis
cross sectional
insulin resistance
glycemic control
drug induced